Status: Recruiting

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

The purpose of this study is to assess the effect of itraconazole on the pharmacokinetics (PK) of AZ14170132.

Participants needed: 32

Trial details

Phase: Phase 1Age: 18+Biological sex: FemaleType: InterventionalSponsor: AstraZenecaUpdated: Sep 29, 2026Locations: 9

Eligibility criteria

Participants with Platinum-resistant, relapsed, high- grade epithelial ovarian c... [+1]

Spinal cord compression or a history of leptomeningeal carcinomatosis. [+4]

Status: Recruiting

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Participants needed: 230

Trial details

Phase: Phase 2Age: 18+Biological sex: FemaleType: InterventionalSponsor: TORL Biotherapeutics, LLCUpdated: Dec 23, 2025Locations: 66

Eligibility criteria

Females ≥18 years of age (or the legal age of consent in the jurisdiction in whi... [+26]

Has not recovered [recovery is defined as National Cancer Institute Common Termi... [+22]

Status: Not yet recruiting

JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of JSKN003 versus investigator's choice of chemotherapy in patients with platinum-resistant, relapsed epithelial Ovarian, primary peritoneal, or fallopian tube cancer.

Participants needed: 430

Trial details

Phase: Phase 3Age: 18+Biological sex: FemaleType: InterventionalSponsor: Jiangsu Alphamab Biopharmaceuticals Co., LtdUpdated: Dec 31, 2024

Eligibility criteria

Voluntary participation and written informed consent. [+8]

Primary platinum-refractory disease. [+10]